India, April 15 -- AstraZeneca Pharma India Ltd announced on Tuesday that it has voluntarily surrendered the marketing authorisation for its prostate cancer treatment drug, Olaparib (Lynparza) 100mg and 150mg, in India due to commercial considerations.
The company had initially received approval to market Olaparib film-coated tablets in both strengths on November 17, 2023. However, according to a regulatory filing, AstraZeneca has now withdrawn the authorisation for these specific indications.
Published by HT Digital Content Services with permission from Dion Global Solutions Limited....